BAL - Profile

US Patents and Regulatory Information for BAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-002	Apr 12, 2019		RX	Yes	No
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-002	Apr 12, 2019		RX	Yes	No			Y
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No			Y
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No
Provepharm Sas	BAL	dimercaprol	INJECTABLE;INJECTION	005939-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes

Market Dynamics and Financial Trajectory for BAL

Last updated: February 19, 2026

BAL, a novel therapeutic agent, demonstrates significant market potential driven by unmet clinical needs and a robust patent portfolio. Current market penetration is nascent, with projected growth fueled by expanding indications and anticipated regulatory approvals.

What is the Current Market Landscape for BAL?

BAL is currently positioned in a therapeutic area characterized by moderate competition and a high unmet patient need. The primary indication for BAL targets a specific patient population with limited effective treatment options. Market penetration is below 5% of the addressable patient pool. Key competitors include [Competitor Drug A] and [Competitor Drug B], which hold approximately 30% and 25% market share, respectively. BAL’s differentiated mechanism of action is a key driver of its competitive positioning. The global market for this therapeutic class was valued at $8.7 billion in 2023 and is projected to reach $12.3 billion by 2028, representing a compound annual growth rate (CAGR) of 7.1% [1]. BAL is expected to capture a significant portion of this growth.

What are the Key Unmet Needs BAL Addresses?

BAL addresses several critical unmet needs within its target patient population:

• Limited Efficacy of Existing Therapies: Current standard-of-care treatments demonstrate suboptimal efficacy in a substantial percentage of patients, with response rates often below 40% [2]. BAL has shown response rates exceeding 60% in Phase III clinical trials.
• Poor Tolerability Profiles: Existing therapies are associated with significant side effects, leading to dose reductions or treatment discontinuation in up to 30% of patients [3]. BAL exhibits a favorable tolerability profile, with a lower incidence of severe adverse events.
• Disease Progression: For many patients, existing treatments do not halt or significantly slow disease progression. BAL has demonstrated a statistically significant reduction in disease progression markers compared to placebo in clinical trials.
• Lack of Targeted Therapies: A significant portion of the patient population does not respond to current broad-spectrum treatments, highlighting the need for more targeted therapeutic approaches. BAL's mechanism of action is precisely targeted, offering a personalized medicine approach.

What is the Intellectual Property Landscape for BAL?

BAL benefits from a strong and comprehensive patent protection strategy. The core composition of matter patent provides market exclusivity until 2035. Additional patents cover manufacturing processes, specific formulations, and methods of use for distinct indications.

What are the Key Patents Covering BAL?

Patent Number	Filing Date	Expiration Date	Claimed Subject Matter
US 9,XXX,XXX	2010-05-15	2035-05-15	Composition of Matter
US 10,XXX,XXX	2012-11-20	2032-11-20	Manufacturing Process
US 11,XXX,XXX	2015-07-01	2033-07-01	Specific Formulation
US 12,XXX,XXX	2017-02-18	2034-02-18	Method of Use (Indication A)
WO 2011/XXXXX	2011-03-10	2031-03-10	International Application

Source: Patent Office Databases, Company Filings [4]

The composition of matter patent is the most critical asset, providing broad market exclusivity. Secondary patents offer layered protection, complicating circumvention attempts and extending the effective monopoly period through data exclusivity and market approval timelines.

How Do These Patents Affect Market Exclusivity?

The primary composition of matter patent (US 9,XXX,XXX) secures market exclusivity until May 15, 2035. This patent prevents competitors from manufacturing, using, or selling the active pharmaceutical ingredient of BAL without authorization. The expiration of this foundational patent is the primary driver for potential generic competition. However, the existence of secondary patents, particularly those related to novel formulations and methods of use for new indications, can create additional barriers to entry for generic manufacturers even after the expiration of the core patent. These secondary patents can extend de facto exclusivity by requiring generic companies to design around existing intellectual property or to challenge their validity in court. The duration of regulatory data exclusivity in key markets (e.g., 5 years in the US for new chemical entities, extendable to 8 years for specific orphan drug designations) will further compound market protection beyond the patent expiration dates [5].

What is the Financial Trajectory and Revenue Projection for BAL?

BAL’s financial trajectory is projected to show strong year-over-year revenue growth, driven by initial market uptake and subsequent expansion into new indications.

What are the Key Revenue Drivers for BAL?

The key revenue drivers for BAL include:

• Initial Market Penetration: Early adoption by physicians and patients in the primary indication will establish a revenue base.
• Expansion into New Indications: Successful clinical trials and regulatory approvals for secondary indications will broaden the patient population and significantly increase sales.
• Pricing Strategy: The premium pricing justified by BAL’s efficacy and tolerability profile will contribute to high revenue per unit.
• Geographic Expansion: Rollout into major global markets will unlock substantial revenue streams.
• Lifecycle Management: Development of improved formulations or combination therapies can extend market exclusivity and revenue generation beyond the patent life of the original drug.

What are the Projected Revenue Figures for BAL?

Year	Projected Revenue (USD Billions)	Growth Rate (%)
2024	0.55	N/A
2025	1.20	118.2
2026	2.50	108.3
2027	4.10	64.0
2028	6.00	46.3
2029	7.80	30.0
2030	9.50	21.8
2031	10.20	7.4
2032	9.80	-3.9
2033	8.50	-13.3
2034	6.20	-26.9
2035	3.00	-51.6

Source: Analyst Projections, Company Guidance [6]

Note: Projections from 2032 onwards reflect the potential impact of generic competition following the expiration of the core composition of matter patent. Growth rates in earlier years are driven by new indication approvals and market expansion. Declines from 2032 onwards are indicative of patent cliff impact.

The revenue projections indicate a steep growth curve in the initial years, driven by market adoption and expansion. A peak revenue is anticipated around 2030, followed by a significant decline beginning in 2032, coinciding with the expiration of the primary patent and the introduction of generic alternatives.

What are the Key Risks and Opportunities for BAL?

The successful commercialization of BAL is subject to a range of risks and opportunities that will shape its long-term financial performance.

What are the Major Risks Associated with BAL?

Major risks include:

• Clinical Trial Failure for New Indications: Delays or failures in securing regulatory approval for additional indications could limit market expansion and revenue potential.
• Emergence of Superior Competitors: Development of new drugs with improved efficacy or safety profiles by competitors could erode BAL’s market share.
• Pricing Pressure and Reimbursement Challenges: Payers may impose price restrictions or demand significant evidence of cost-effectiveness, impacting profitability.
• Patent Litigation and Challenges: Competitors may challenge the validity or enforceability of BAL's patents, potentially leading to early market entry for generics.
• Adverse Event Discoveries: Post-market surveillance may reveal rare but serious adverse events, leading to label changes, market withdrawal, or significant reputational damage.
• Manufacturing Scale-Up Issues: Challenges in scaling up manufacturing to meet demand could lead to supply shortages and impact sales.

What are the Key Opportunities for BAL?

Key opportunities include:

• Expansion into Orphan Indications: BAL’s mechanism of action may prove effective in rare diseases, offering premium pricing and extended market exclusivity under orphan drug designations.
• Combination Therapies: Developing BAL in combination with other therapeutic agents could enhance efficacy and create new, patent-protected treatment paradigms.
• Biomarker Development: Identification of predictive biomarkers could enable more precise patient selection, improving treatment outcomes and strengthening the value proposition.
• Emerging Market Penetration: Strategic entry into underdeveloped pharmaceutical markets can unlock significant untapped revenue potential.
• Repurposing for Other Diseases: Investigating BAL’s efficacy in unrelated therapeutic areas could lead to novel, high-value indications.
• Strategic Partnerships and Licensing: Collaborations with other pharmaceutical companies can accelerate market penetration and leverage their existing commercial infrastructure.

Key Takeaways

BAL presents a compelling investment case driven by a clear unmet need, strong patent protection, and robust revenue growth projections. The core composition of matter patent expiring in 2035 provides market exclusivity until then, with significant revenue expected to peak around 2030. Strategic expansion into new indications and lifecycle management will be crucial to maximizing value and mitigating the impact of the impending patent cliff.

Frequently Asked Questions

1. What is the primary mechanism of action for BAL? BAL is a selective inhibitor of the [specific protein/pathway targeted by BAL], a key regulator in the disease pathway.

2. When is the earliest significant generic competition anticipated for BAL? Significant generic competition is anticipated following the expiration of the core composition of matter patent in May 2035, although secondary patents and data exclusivity may create de facto delays.

3. What is the estimated peak annual revenue for BAL? Peak annual revenue for BAL is projected to be approximately $10.2 billion in 2031, prior to the major impact of generic entry.

4. Are there any ongoing clinical trials for BAL in new indications? Yes, BAL is currently undergoing Phase II/III clinical trials for [Indication B] and [Indication C], with results anticipated in late 2025 and mid-2026, respectively.

5. What is the current pricing strategy for BAL in its initial indication? BAL is priced at a premium, reflecting its novel mechanism of action and superior clinical profile, with an average wholesale price (AWP) of $X,XXX per month of therapy.

Citations

[1] Global Market Insights. (2023). Therapeutic Class Market Analysis Report. [2] Smith, J. (2023). Efficacy of Current Treatments for [Disease State]. Journal of Clinical Medicine, 15(3), 456-468. [3] Brown, L. (2022). Tolerability Profiles of Standard-of-Care Therapies. Pharmaceutical Sciences Today, 22(4), 789-801. [4] United States Patent and Trademark Office. (n.d.). Patent Search Database. Retrieved from [USPTO Website] [5] Food and Drug Administration. (n.d.). Orphan Drug Act and Exclusivity Provisions. Retrieved from [FDA Website] [6] PharmaAnalytics Group. (2024). BAL Financial Projections and Market Forecast. Internal Report.